Evidence mapPaperPMID 42187743Full record

ArticleBiology2026

Uncovering Potential Neutrophil-Related Biomarkers for Early AMI Diagnosis.

Yuwei Liu, Yun Zhang, Lucheng Wang, Diru Yao, Ebenezeri Erasto Ngowi, Moussa Omorou, Ning Hou, Weibo Dai, Longlong Wang, Guihua Yue and 1 more

Abstract read
In one paragraph

Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuwei LiuSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yun ZhangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 550004, China.
Lucheng WangSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
Diru YaoZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Ebenezeri Erasto NgowiZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Moussa OmorouZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.ORCID 0000-0002-2473-5891
Ning HouSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.ORCID 0000-0002-7745-4946
Weibo DaiPharmacology Laboratory, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated with Guangzhou University of Traditional Chinese Medicine, Zhongshan 528400, China.
Longlong WangDepartment of Clinical Medicine of Integrated Traditional Chinese and Western Medicine, The Affiliated International Zhuang Medicine Hospital of Guangxi University of Chinese Medicine, Nanning 530200, China.
Guihua YueDepartment of Clinical Medicine of Integrated Traditional Chinese and Western Medicine, The Affiliated International Zhuang Medicine Hospital of Guangxi University of Chinese Medicine, Nanning 530200, China.
Aijun QiaoSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.ORCID 0000-0001-7545-3395

Funding

High-level Innovative Research Institute of the Department of Science and Technology of Guangdong Province 2021B0909050003High-level New R&D Institute of the Department of Science and Technology of Guangdong Province 2019B090904008Lin Gang Laboratory LGL-2612-22National Natural Science Foundation of China 82270925National Natural Science Foundation of China 82470892State Key Laboratory of Drug Research SKLDR-2025-KF-07Traditional Chinese medicine inheritance innovation development research project of Zhongshan City 2024B3002Zhoushan Science and Technology Bureau CXTD2023009
6 · The paper itself

Abstract

Early diagnosis of AMI is crucial for improving patient outcomes, yet current clinical tools often lack the requisite sensitivity and specificity for reliable early detection. As neutrophils are the first innate immune responders mobilized following infarction, we employed an integrated multi-omics and machine learning approach to identify neutrophil-driven molecular signatures with diagnostic potential. By analyzing multiple peripheral blood transcriptomic datasets, we conducted differential expression and immune infiltration analyses, followed by machine learning-based feature selection to pinpoint key genes linked to neutrophil activity. Integration of these findings with single-cell transcriptomic data further clarified the neutrophil-specific expression patterns of candidate genes during AMI progression. Using a joint diagnostic model, we identified MCEMP1, NFE2, and AQP9 as the most informative predictors, with MCEMP1 emerging as the primary contributor. Experimental validation in a murine model of myocardial infarction (MI) confirmed rapid upregulation of MCEMP1 after injury, closely mirroring the kinetics of neutrophil infiltration. Collectively, these findings delineate a neutrophil-associated molecular profile of early AMI and highlight MCEMP1 as a promising noninvasive biomarker and a potential therapeutic target for modulating neutrophil-driven myocardial injury.

Indexed as

acute myocardial infarctionbiomarkerinflammationmachine learningneutrophils

Identifiers

PMID42187743
PMCPMC13203664

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.